Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9142197 | 0.94 | TLR8 (0.41) | TLR8PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7497418 | 0.86 | — | — | |
| SCHEMBL11261285 | 0.81 | ALDH1A1 (0.35) | — | |
| SCHEMBL27378739 | 0.78 | TYR (0.37) | TLR8 | |
| SCHEMBL370841 | 0.78 | TDP1 (0.35) | TLR8 | |
| SCHEMBL1010195 | 0.77 | — | — | |
| SCHEMBL31013116 | 0.77 | TYR (0.40) | — | |
| SCHEMBL28300224 | 0.77 | LIPG (0.38) | — | |
| SCHEMBL27671187 | 0.77 | LIPG (0.38) | — | |
| SCHEMBL1880278 | 0.77 | ALOX5 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105792844-A | Combination of anti-FGFR2 antibody and other agent | 第三共株式会社 | 2016-07-20 | — | — | CN | claimed |
| EP-3440071-A1 | FUSED HETEROCYCLIC ORGANIC COMPOUNDS AND USES THEREOF | Perlara PBC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-10166236-B2 | Pharmaceutical formulations comprising substituted pyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazines for treating lysosomal storage disorders | PERLARA PBC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170281635-A1 | FUSED HETEROCYCLIC ORGANIC COMPOUNDS AND USES THEREOF | PERLARA PBC | 2017-10-05 | — | — | US | disclosed |
| WO-2017165311-A1 | FUSED HETEROCYCLIC ORGANIC COMPOUNDS AND USES THEREOF | PERLSTEIN LAB PBC (US) | 2017-09-28 | — | — | WO | disclosed |
| CN-105792844-A | Combination of anti-FGFR2 antibody and other agent | 第三共株式会社 | 2016-07-20 | — | — | CN | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8907092-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005007658-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| CN-1498885-A | Synthesizing 3-acylamino pyrazole | 伊斯曼柯达公司 | 2004-05-26 | — | — | CN | disclosed |
| EP-0788358-B1 | USE OF PYRAZOLE COMPOUNDS FOR THE TREATMENT OF GLOMERULONEPHRITIS, CANCER, ATHEROSCLEROSIS OR RESTENOSIS | MILLENNIUM PHARM INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-5916908-A | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases | COR THERAPEUTICS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0788358-A2 | PHARMACEUTICAL PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | COR THERAPEUTICS, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996014843-A2 | PHARMACEUTICAL PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | COR THERAPEUTICS, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5132424-A | Anticholesterol, treatment of atherosclerosis | THE UPJOHN COMPANY (US) | 1992-07-21 | — | — | US | disclosed |
| EP-0425541-A1 | PYRAZOLO-AZOLO-PYRIMIDINE-DIONES | THE UPJOHN COMPANY (US) | 1991-05-08 | — | — | EP | disclosed |
| WO-1990001031-A1 | PYRAZOLO-PYRROLO-PYRIMIDINE-DIONES | THE UPJOHN COMPANY (US) | 1990-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281635-A1 | FUSED HETEROCYCLIC ORGANIC COMPOUNDS AND USES THEREOF | NPC1L1, NPC1, LIPA | TLR8 4519/4885PI4KA 1352/4885PI4K2B 1187/4885 |
| US-10166236-B2 | Pharmaceutical formulations comprising substituted pyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazines for treating lysosomal storage disorders | NPC1L1, NPC1, GBA1 | TLR8 4485/4885PI4KA 645/4885PI4K2B 347/4885 |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | TLR8 3902/4885PI4KA 2402/4885PI4K2B 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.